Lilly Bows To The Ftc

ELI LILLY'S $4 BILLION PURchase of a major drug benefits manager is likely to get a green light from trustbusters at the Federal Trade Commission after all--with strings. The company has agreed to FTC conditions meant to ensure that its acquisition of McKesson's PCS unit won't diminish competition: PCS will make its shopping list of drugs available to all drugmakers and will set up a "firewall" to prevent information on bids from rival drugmakers from flowing to Lilly, say sources close to the talks. Consumer advocates and trustbusters fear that drug benefits managers bought by pharmaceutical companies may favor their owners' products over those of rivals.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.